Education
About Us
Working with TipRanks
Follow Us
Biogen Inc. (BIIB)
NASDAQ:BIIB
Top Page
Biogen
(NASDAQ:BIIB)
Select Model
Select Model
Rating:64Neutral
Price Target:
$215.00
▲(14.33% Upside)
Action:DowngradedDate:02/07/26
BIIB scores as a mid-range opportunity driven primarily by stable financials (profitability, free cash flow, and manageable leverage). The earnings outlook is mixed: growth products and pipeline progress are positives, but 2026 revenue is guided down with ongoing legacy MS erosion and timing/reimbursement risks. Technically the trend is strong but appears overbought, while valuation is not especially cheap at ~22.8x earnings and lacks a dividend yield input.
Positive Factors
Pipeline Advancements
Biogen's initiation of multiple Phase III studies indicates a robust pipeline, which is crucial for long-term growth and maintaining competitive advantage in the biotech industry.
Cash Flow Management
Strong cash flow management enhances Biogen's ability to invest in R&D and strategic initiatives, supporting sustainable growth and financial resilience.
Strategic Collaborations
Strategic collaborations, like the agreement with Vanqua, expand Biogen's portfolio and enhance its R&D capabilities, positioning it for long-term success in the biotech sector.
Negative Factors
Declining Profitability Margins
Declining profitability margins suggest challenges in cost management and operational efficiency, which could impact Biogen's long-term financial health and competitiveness.
MS Revenue Challenges
Competitive pressures in the MS market, particularly from generics, threaten Biogen's revenue streams and market position, potentially affecting long-term growth.
Arbitration with Eisai
The arbitration with Eisai highlights potential partnership challenges, which could disrupt strategic collaborations and impact Biogen's market strategy in Europe.
Biogen (BIIB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.60B
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)21.4
Beta (1Y)0.64
Revenue Growth5.00%
EPS Growth-1.03%
CountryUS
Employees7,605
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.99
Shares Outstanding146,758,530
10 Day Avg. Volume875,643
30 Day Avg. Volume1,292,956
Financial Highlights & Ratios
PEG Ratio-0.95
Price to Book (P/B)1.41
Price to Sales (P/S)2.63
P/FCF Ratio12.59
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.98
Forecast
1Y Price Target
$205.30Price Target Upside9.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
EPS Forecast (FY)15.82
Revenue Forecast (FY)$9.44B
Biogen Business Overview & Revenue Model
Company DescriptionBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyBiogen generates revenue primarily through the sale of its pharmaceutical products, particularly those targeting neurological disorders. The company's key revenue streams include sales from its multiple sclerosis therapies, which account for a significant portion of its income. Additionally, Biogen earns revenue from royalties and collaborations with other pharmaceutical companies, often involving joint ventures or co-development agreements for new therapies. Their partnership with companies like Eisai for Alzheimer's treatments also plays a crucial role in their financial strategy. Furthermore, Biogen invests in research and development to create new drugs, which, once approved, can significantly enhance its product portfolio and drive future revenues.
Biogen Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Biogen is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Biogen is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyBiogen Earnings Call Summary
Earnings Call Date:Feb 06, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Neutral
The call conveyed balanced optimism: Biogen reported strong operating cash flow, solid EPS, a growing cohort of recently launched 'growth' products and meaningful pipeline and regulatory progress (priority review, breakthrough designation, new INDs and acquisition activity). These positives are tempered by near‑term revenue guidance calling for a mid‑single‑digit decline in 2026, ongoing competitive pressures on legacy MS products (generics and biosimilars), one‑time charges that weighed on GAAP results and reimbursement/inventory timing uncertainties that could dampen near‑term revenue trajectories. The company is investing for launches and pipeline progression while managing legacy declines.Q4-2025 Updates
Positive Updates
Strong EPS, cash generation and balance sheet
Q4 non-GAAP diluted EPS $1.99; FY2025 non-GAAP diluted EPS $15.28 (came in above expectations). Free cash flow $2.1B for the year; cash and marketable securities $4.2B; net debt $2.0B; FY2025 total revenue $9.9B, up ~2% versus 2024.
Growth products driving momentum
Growth products generated $3.3B in FY2025 and >$800M in Q4 2025. Management highlighted strong year-over-year expansion for the growth portfolio (company commentary referenced substantial YoY increases for the growth cohort). Several recently launched products (since 2023) — Lekembi, Skyclaris, Xerxuve, and Calcadi — now generate >$1B combined.
Market leadership for anti-amyloid therapy (Lekembi)
Lekembi reported >60% share of the anti-amyloid therapy market; persistency after plaque‑removal reported at ~70%. Priority review secured for the subcutaneous induction (iClick) with a PDUFA date of May 24, 2026 — potential to reduce infusion burden and broaden access.
Notable product commercial wins
Xerxuve more than doubled sales in 2025. Skyclaris Q4 global revenue $133M, up ~30% YoY (U.S. Q4 $89M); Akembi end‑market sales booked by Eisai ~ $134M in Q4, noted as a step increase (+1054% versus Q3 2025 and Q4 2024 comparisons by management). VUMERITY FY2025 revenue $747M, +19% YoY.
Pipeline expansion and regulatory designations
Pipeline broadened materially during 2025: lidifolumab (litifolumab) received FDA Breakthrough Therapy designation for cutaneous lupus; multiple registrational readouts expected (e.g., litifolumab TOPAZ‑2 readout by end of 2026, BIB080 tau phase 2 mid‑year, SPINRAZA high‑dose PDUFA in April 2026). BTK degrader (BIG145) initiated phase 1 in healthy volunteers.
Strategic BD and acquisition activity
Acquisition of Alcion Therapeutics announced to improve delivery options for intrathecal therapies (e.g., potential convenience improvements for SPINRAZA). New collaborations completed in Q4 with Vanqua and Dara Therapeutics to broaden portfolio and R&D options.
Negative Updates
2026 revenue guidance shows near‑term decline
Company expects full‑year 2026 total revenue to decline by a mid single‑digit percentage versus 2025; full‑year non‑GAAP diluted EPS guidance $15.25–$16.25 (flat to modestly higher vs FY2025). Management expects MS revenue excluding VUMERITY to decline by a mid‑teen percentage in 2026.
Legacy MS franchise competitive pressures
TECfidera experienced accelerating generic erosion in Europe (expected to continue in 2026). Introduction of a biosimilar for Tysabri in the EU noted, creating continued pressure on legacy MS revenues.
One‑time charges and IPR&D impact on GAAP results
Q4 reflected $222M of IPR&D charges tied to BD transactions and roughly $180M of one‑time GAAP operating charges (litigation and other matters). Management noted a $1.26 per‑share EPS impact from Q4 business development transactions.
SPINRAZA and other product headwinds
Global SPINRAZA Q4 revenue $356M; full‑year SPINRAZA revenue down ~2% YoY. Outside‑U.S. revenues were impacted by timing of shipments. SPINRAZA remains resilient but faces competitive and timing challenges.
Reimbursement and inventory/timing uncertainties
Subcutaneous iClick induction for Lekembi currently covered via Part D formulary exemptions with full Part D reimbursement not expected until January 1, 2027 (per management). Q4 Skyclaris ex‑U.S. result included ~$12M net pricing adjustments; U.S. Skyclaris sequential uplift benefited from a ~$9M favorable inventory dynamic expected to be drawn down in Q1 2026. VUMERITY Q4 U.S. revenue also negatively impacted by shipment timing.
Near‑term flat/limited growth in manufacturing
Contract manufacturing revenue expected to be roughly $300M in each half of 2026 — implying limited near‑term growth in that business line.
Clinical/regulatory execution risk remains
Several important registrational readouts are upcoming (e.g., litifolumab for SLE, BIB080 phase 2 for tau, selzartamab data for AMR). Positive outcomes are material to the company’s growth thesis but remain uncertain and will determine timing of future launches (possible launches expected in 2028 if Phase III are positive).
Company Guidance
Biogen guided full‑year 2026 non‑GAAP diluted EPS of $15.25–$16.25 (versus $15.28 in FY2025 and Q4 2025 non‑GAAP EPS of $1.99) and expects total revenue to decline a mid‑single‑digit percentage versus FY2025 revenue of $9.9B (FY25 +2% vs 2024); the company said MS revenue excluding VUMERITY should decline by a mid‑teens percentage, contract manufacturing revenue is expected to be roughly $300M per half (~$600M/year), gross margin roughly consistent with 2025, and core OpEx roughly flat (with Q1 2026 expense ~10% higher YoY). For context, growth products generated $3.3B in FY2025 (and >$800M in Q4), SPINRAZA Q4 global revenue was $356M (full year down 2% YoY), VUMERITY FY25 revenue was $747M (Q4 $181M), Skyclaris Q4 global revenue was $133M (+30% YoY) and Akembi end‑market Q4 sales were about $134M; FY2025 free cash flow was $2.1B, cash & marketable securities $4.2B with $2.0B net debt, and Q4 results included ~$222M of IPR&D charges, ~ $180M of one‑time GAAP charges and a $1.26 per‑share EPS impact from Q4 business‑development transactions.Biogen Financial Statement Overview
Summary
Solid profitability, consistent positive free cash flow, and a healthier leverage profile support financial stability. However, multi-year revenue contraction and a step-down in margins/cash flow momentum temper the financial outlook.Income Statement
Biogen remains solidly profitable with strong gross and operating margins in 2025, but the earnings profile has become less consistent versus earlier years. Revenue has been declining each year across the period provided, and profitability has compressed from the 2020–2022 highs (notably a much lower net margin in 2023–2025 versus 2022). The company still generates meaningful operating profit, yet the multi-year revenue contraction and margin volatility temper the outlook.62
Positive
Balance Sheet
The balance sheet looks healthy overall: leverage is moderate with debt-to-equity improving materially from 2020–2021 levels to a lower level by 2025, and equity has grown over time. Returns on equity are positive but have stepped down meaningfully from peak levels (especially versus 2020 and 2022), indicating less efficient profit generation on the capital base recently. Net, Biogen appears financially stable with manageable leverage, though profitability on equity has weakened.74
Positive
Cash Flow
Cash generation remains a key strength, with positive operating cash flow and free cash flow in every year shown. Free cash flow generally tracks net income well (free cash flow close to net income), supporting earnings quality, but cash flows have become less robust recently: free cash flow declined in 2025 and operating cash flow is down from the strongest historical levels. Overall cash conversion is good, but the recent downshift in cash flow momentum is a watch item.68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.81B | 9.68B | 9.84B | 10.17B | 10.98B |
| Gross Profit | 6.91B | 7.37B | 7.30B | 7.90B | 8.87B |
| EBITDA | 3.10B | 3.00B | 2.38B | 3.54B | 3.92B |
| Net Income | 1.29B | 1.63B | 1.16B | 3.05B | 1.56B |
Balance Sheet | |||||
| Total Assets | 29.44B | 28.05B | 26.84B | 24.55B | 23.88B |
| Cash, Cash Equivalents and Short-Term Investments | 3.82B | 2.38B | 1.05B | 4.89B | 3.80B |
| Total Debt | 6.95B | 6.63B | 7.34B | 6.61B | 7.60B |
| Total Liabilities | 11.18B | 11.33B | 12.05B | 11.17B | 12.92B |
| Stockholders Equity | 18.26B | 16.72B | 14.80B | 13.40B | 10.90B |
Cash Flow | |||||
| Free Cash Flow | 2.05B | 2.52B | 1.24B | 1.14B | 3.38B |
| Operating Cash Flow | 2.20B | 2.88B | 1.55B | 1.38B | 3.64B |
| Investing Cash Flow | -1.37B | -799.20M | -4.09B | 1.59B | -563.70M |
| Financing Cash Flow | -301.90M | -683.50M | 137.00M | -1.76B | -2.09B |
Biogen Technical Analysis
Neutral
188.05
Price Trends
181.80
Positive
171.74
Positive
152.84
Positive
Market Momentum
2.97
Positive
50.40
Neutral
24.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIIB, the sentiment is Neutral. The current price of 188.05 is below the 20-day moving average (MA) of 190.89, above the 50-day MA of 181.80, and above the 200-day MA of 152.84, indicating a neutral trend. The MACD of 2.97 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 24.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIIB.
Biogen Risk Analysis
Biogen disclosed 30 risk factors in its most recent earnings report. Biogen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biogen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $186.25B | 21.97 | 40.49% | 2.52% | 2.76% | 6407.19% | |
71 Outperform | $207.92B | 27.28 | 106.10% | 3.00% | 11.03% | 65.22% | |
71 Outperform | $126.95B | 18.03 | 40.53% | 4.84% | 1.26% | ― | |
67 Neutral | $117.79B | 15.90 | 38.48% | 3.41% | 5.97% | 128.66% | |
64 Neutral | $27.60B | 21.36 | 7.39% | ― | 5.00% | -1.03% | |
60 Neutral | $414.21B | 98.30 | 9999.00% | 2.87% | 7.40% | -53.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BIIB
Biogen
188.05
45.40
31.83%
AMGN
Amgen
385.70
83.01
27.42%
BMY
Bristol-Myers Squibb
62.34
5.76
10.18%
GILD
Gilead Sciences
150.03
38.41
34.41%
GSK
GlaxoSmithKline
58.29
21.33
57.72%
ABBV
AbbVie
234.26
33.24
16.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.